Search

Protagonist Therapeutics Inc

Fechado

SetorSaúde

135.94 2.91

Visão Geral

Variação de preço das ações

24h

Atual

Mín

132.13

Máximo

137.77

Indicadores-chave

By Trading Economics

Rendimento

-82M

3.8M

Vendas

49M

56M

P/E

Médio do Setor

131.197

64.641

EPS

0.05

Margem de lucro

6.711

Funcionários

131

EBITDA

46M

2.7M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

-0.88% downside

Dividendos

By Acuity

Próximos Ganhos

11 de ago. de 2026

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

2.3B

8.7B

Abertura anterior

133.03

Fecho anterior

135.94

Sentimento de Notícias

By Acuity

42%

58%

133 / 340 Ranking em Healthcare

Protagonist Therapeutics Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

3 de ago. de 2026, 19:36 UTC

Protagonist Therapeutics Inc shares are lower today, continuing a decline since Friday. The stock is near the lower end of its one-month range.

31 de jul. de 2026, 19:36 UTC

Correlated Moves

Protagonist Therapeutics Inc is lower today amid broader weakness in the Biotechnology sector. Earlier in the session, shares pulled back from a high.

30 de jul. de 2026, 21:02 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, amid notable volatility and significant price swings since Thursday's close.

29 de jul. de 2026, 19:43 UTC

Macro Event

Protagonist Therapeutics Inc shares are lower amid market volatility following the Federal Reserve's decision to maintain interest rates, reflecting broader uncertainty.

28 de jul. de 2026, 21:01 UTC

Protagonist Therapeutics Inc shares are higher in after-market trading, maintaining a notable gain since Tuesday's close, despite no specific news identified.

27 de jul. de 2026, 20:02 UTC

Social Media

Protagonist Therapeutics shares are lower despite Jefferies raising its price target to $171 and Cowen increasing its peak royalty revenue forecast to $1.4 billion.

22 de jul. de 2026, 19:42 UTC

News

Protagonist Therapeutics Inc is trading lower today, continuing a decline since Tuesday amid rising crude oil prices and market tensions related to Iran.

21 de jul. de 2026, 19:06 UTC

Protagonist Therapeutics Inc shares are higher today, continuing an upward trend since Monday's close, supported by gains in the semiconductor sector.

20 de jul. de 2026, 19:41 UTC

News
Social Media

Protagonist Therapeutics shares are lower as analysts raise price targets and revenue forecasts ahead of Q2 earnings, despite a noted 0% probability of success for PN-881.

Comparação entre Pares

Variação de preço

Protagonist Therapeutics Inc Previsão

Preço-alvo

By TipRanks

-0.88% parte inferior

Previsão para 12 meses

Média 131.11 USD  -0.88%

Máximo 165 USD

Mínimo 110 USD

Com base em 10 analistas de Wall Street que oferecem metas de preço de 12 meses para Protagonist Therapeutics Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

10 ratings

9

Comprar

1

Manter

0

Vender

Sentimento

By Acuity

133 / 340 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Protagonist Therapeutics Inc

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.
help-icon Live chat